Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A. Hanania, John G. Matthews, Petr Kopecký et al.|The Lancet Respiratory Medicine|2016Cited by 465
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L. Meulmeester, Simon Couillard, Samuel Mailhot-Larouche et al.|The Lancet Respiratory Medicine|2025Cited by 69